Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Prochlorperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 10/20 | 0.98 |
| ▸ | MAPT | P10636 | 8/20 | 0.98 |
| ▸ | MAPK1 | P28482 | 7/20 | 0.98 |
| ▸ | LMNA | P02545 | 7/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 7/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 7/20 | 0.98 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.98 |
| ▸ | HTR2A | P28223 | 7/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.98 |
| ▸ | HRH1 | P35367 | 7/20 | 0.98 |
| ▸ | DRD3 | P35462 | 7/20 | 0.98 |
| ▸ | HTR1A | P08908 | 7/20 | 0.98 |
| ▸ | TP53 | P04637 | 6/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.98 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.98 |
| ▸ | ADRA2B | P18089 | 6/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prochlorperazine SCHEMBL2506559 | 1.00 | DRD2 (0.98) | DRD2MAPTMAPK1LMNASMN1; SMN2 | |
| Prochlorperazine SCHEMBL18429 | 0.99 | DRD2 (1.00) | DRD2MAPTMAPK1LMNASMN1; SMN2 | |
| Prochlorperazine SCHEMBL29369439 | 0.99 | DRD2 (1.00) | DRD2MAPTMAPK1LMNASMN1; SMN2 | |
| Prochlorperazine SCHEMBL29358207 | 0.99 | DRD2 (1.00) | DRD2MAPTMAPK1LMNASMN1; SMN2 | |
| Prochlorperazine SCHEMBL14126977 | 0.99 | DRD2 (1.00) | DRD2MAPTMAPK1LMNASMN1; SMN2 | |
| Prochlorperazine SCHEMBL133595 | 0.98 | DRD2 (0.98) | DRD2MAPTMAPK1LMNASMN1; SMN2 | |
| Perphenazine SCHEMBL28086447 | 0.93 | MAPT (0.91) | DRD2MAPTMAPK1LMNASMN1; SMN2 | |
| Perphenazine SCHEMBL5307579 | 0.93 | MAPT (0.91) | DRD2MAPTMAPK1LMNASMN1; SMN2 | |
| Prochlorperazine SCHEMBL10891828 | 0.92 | MAPT (0.90) | DRD2MAPTMAPK1LMNASMN1; SMN2 | |
| SCHEMBL13485632 | 0.92 | MAPT (0.86) | DRD2MAPTMAPK1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6121276-A | ORALLY ADMINISTERING DSAGE OF APOMORPHINE TOGETHER WITH ANTIEMETIC PRIOR TO INTERCOURSE; SIDE EFFECT REDUCTION | PENTECH PHARMACEUTICALS, INC. (US) | 2000-09-19 | — | — | US | claimed |
| CN-116507327-A | Chewable formulations | 礼蓝动物保健有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-114846012-A | 2-isoindole-1, 3, 4-oxadiazole derivatives useful as HDAC6 inhibitors | 武田药品工业株式会社 | 2022-08-02 | — | — | CN | disclosed |
| US-11033510-B2 | Anti-inflammatory pharmaceutical compositions and methods of administration | LANCE L. GOOBERMAN (US) | 2021-06-15 | — | — | US | disclosed |
| CN-112955124-A | Oral film compositions and dosage forms having precise active dissolution profiles | 阿奎蒂夫疗法公司 | 2021-06-11 | — | — | CN | disclosed |
| CN-112585690-A | System and method for producing individualized individual unit doses containing a pharmaceutically active substance | 阿奎斯蒂弗医疗股份有限公司 | 2021-03-30 | — | — | CN | disclosed |
| CN-112384223-A | Pharmaceutical composition containing poorly soluble basic drug | 中外制药株式会社 | 2021-02-19 | — | — | CN | disclosed |
| CN-212167407-U | Compounding device is used in production of hydrochloric acid lorcyclizine | 焦作福瑞堂制药有限公司 | 2020-12-18 | — | — | CN | disclosed |
| EP-3095442-B1 | INJECTABLE SUSPENSIONS HAVING IMPROVED INJECTABILITY PROPERTIES | ALKERMES CONTROLLED THERAPEUTICS INC (US) | 2020-11-18 | — | — | EP | disclosed |
| CN-211936518-U | Refining plant of hydrochloric acid lorcyclizine production usefulness | 焦作福瑞堂制药有限公司 | 2020-11-17 | — | — | CN | disclosed |
| US-6284283-B1 | ATOMIZING USING MULTIFLUID ATOMIZATION DISPERSED SYSTEM COMPRISING BIOLOGICALLY ACTIVE AGENT AND SOLVENT TO PRODUCE DROPLETS; FREEZING; REMOVING SOLVENT FROM FROZEN DROPLETS TO PRODUCE FRIABLE MICROSTRUCTURES; DISPERSION; FRAGMENTING | ALKERMES CONTROLLED THERAPEUTICS, INC. | 2001-09-04 | — | — | US | disclosed |
| WO-2001058428-A1 | METHOD OF PREPARING A SUSTAINED RELEASE COMPOSITION | ALKERMES CONTROLLED THERAPEUTICS, INC. (US) | 2001-08-16 | — | — | WO | disclosed |
| US-6264987-B1 | MIXING; CONTROLLING TEMPERATURE | ALKERMES CONTROLLED THERAPEUTICS INC. II | 2001-07-24 | — | — | US | disclosed |
| EP-1094799-A1 | APOMORPHINE-CONTAINING DOSAGE FORMS FOR AMELIORATING MALE ERECTILE DYSFUNCTION | PENTECH PHARMACEUTICALS, INC. (US) | 2001-05-02 | — | — | EP | disclosed |
| WO-2001028525-A2 | METHOD OF PRODUCING SUB-MICRON PARTICLES OF BIOLOGICALLY ACTIVE AGENTS | ALKERMES CONTROLLED THERAPEUTICS, INC. (US) | 2001-04-26 | — | — | WO | disclosed |
| US-6121276-A | ORALLY ADMINISTERING DSAGE OF APOMORPHINE TOGETHER WITH ANTIEMETIC PRIOR TO INTERCOURSE; SIDE EFFECT REDUCTION | PENTECH PHARMACEUTICALS, INC. (US) | 2000-09-19 | — | — | US | disclosed |
| WO-1999066916-A1 | APOMORPHINE-CONTAINING DOSAGE FORMS FOR AMELIORATING MALE ERECTILE DYSFUNCTION | PENTECH PHARMACEUTICALS, INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| US-5989463-A | FORMING SOLID PARTICLE MATRIX BY ATOMIZING/DESOLVENTIZING A CONTINUOUS PHASE IN WHICH A POLYMER AND A BIOACTIVE MATERIAL, I.E, DRUG, ARE BOTH DISSOLVED | ALKERMES CONTROLLED THERAPEUTICS, INC. (US) | 1999-11-23 | — | — | US | disclosed |
| US-5804218-A | ORALLY ADMINISTERING INSOLUBLE ZINC SALT TO ADSORB SOLUBLE BILIRUBIN IN GASTROINTESTINAL TRACT | BRIGHAM & WOMEN'S HOSPITAL, INC. (US) | 1998-09-08 | — | — | US | disclosed |
| WO-1998007412-A1 | CONTROLLED RELEASE MICROPARTICLES WITH A HYDROPHOBIC MATERIAL | ALKERMES CONTROLLED THERAPEUTICS, INC. (US) | 1998-02-26 | — | — | WO | disclosed |